Shuimu Biosciences is a leading brand in the field of cryo-electron microscopy (cryo-EM) and AI drug discovery. Founded in 2017 in Beijing, China, Shuimu is committed to bringing the power of cryo-EM to innovative therapeutics developers. Their top-notch cryo-EM platform offers exceptional structure determination capabilities, enabling pharma and biotech companies to accelerate rational drug design.

With a team of experts in structural biology, biochemistry, microscopy, and computation, Shuimu provides comprehensive solutions for structure-based drug design. Their services include cryo-EM structure determination, protein production, lead discovery, and computer-aided drug design (CADD). Shuimu's platform consists of state-of-the-art cryo-EM data collection centers and an in-house protein production laboratory.

They are continually expanding their capacity to make cryo-EM more accessible to their partners worldwide. The brand is driven by a competent team, including renowned scientists and researchers in the field of cryo-EM. Shuimu's co-founders and experts have extensive experience and expertise in cryo-EM methodology, atomic structure modeling, electron microscopes, data processing, and immunology.

Shuimu Biosciences is dedicated to pushing the boundaries of drug discovery through their expertise, infrastructure, and cutting-edge technologies. Joining forces with them can lead to game-changing discoveries in the world of drug development. Partner with Shuimu to unlock the potential of cryo-EM and revolutionize the future of therapeutics